Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 4/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MTTP | P55157 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | BMP1 | P13497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185095 | 0.93 | LMNA (0.46) | CXCR3MAPK14LMNAMAPTHTT | |
| SCHEMBL197755 | 0.89 | LMNA (0.48) | CXCR3LMNAMAPTHTTNPSR1 | |
| SCHEMBL184815 | 0.86 | ACLY (0.49) | CXCR3LMNAMAPTHTTNPSR1 | |
| SCHEMBL185526 | 0.85 | MAPK14 (0.54) | CXCR3MAPK14LMNAMAPTACLY | |
| SCHEMBL184371 | 0.79 | ALDH1A1 (0.41) | CXCR3LMNAMAPTHTTNPSR1 | |
| SCHEMBL15164047 | 0.77 | ACLY (0.52) | CXCR3LMNAMAPTHTTNPSR1 | |
| SCHEMBL184106 | 0.74 | ACLY (0.61) | CXCR3LMNAMAPTHTTNPSR1 | |
| SCHEMBL185158 | 0.74 | BCL2 (0.60) | CXCR3MAPK14LMNAHTTACLY | |
| SCHEMBL185044 | 0.74 | BCL2 (0.58) | CXCR3LMNAMAPTHTTNPSR1 | |
| SCHEMBL15157760 | 0.73 | ACLY (0.58) | ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | claimed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | claimed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2297103-B1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | CXCR3 2556/4885MAPK14 2731/4885LMNA 886/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | CXCR3 3367/4885MAPK14 2253/4885LMNA 358/4885 |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | CXCR3 2539/4885MAPK14 1213/4885LMNA 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.